Autopsy report · NCT02365233

Fatty Liver Study in Patients With Type II Diabetes

“IRB withheld the data due to inadequate supporting documentation”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 8 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

The University of Texas Medical Branch, Galveston

Sponsor type

University, hospital or other

Conditions

Type II Diabetes; Nonalcoholic Fatty Liver

Interventions

DPP4 inhibitor; Pioglitazone; Lantus insulin

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
  “Limited resources; IRB approval was not maintained” (66% match in meaning)
• RCT Investigating Pre-cesarean Vaginal Wash of Chlorhexidine vs Povidone-iodine for Patient With Ruptured Amniotic Membrane.
  “The study was withdrawn from the IRB” (66% match in meaning)
• Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
  “Study did not receive IRB approval.” (65% match in meaning)
• Intestinal Microbiome Post-Azythromycin/Albendazole Treatment
  “We were not able to secure IRB approval in the timeline necessary to do this study.” (64% match in meaning)
• Antibiotics and Tissue Expanders in Breast Reconstruction
  “The study was withdrawn prior to IRB approval.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.